Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals

Journal of Virology

Volumn 78, Issue 13, 2004, Pages 7016-7022

  Lizeng, Qin ^a   Nilsson, Charlotta ^a,b,f   Sourial, Samer ^c   Andersson, Sören ^b,d   Larsen, Olav ^e   Aaby, Peter ^e   Ehnlund, Mariethe ^a   Björling, Ewa ^c  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e BANDIM HEALTH PROJECT   (Guinea-Bissau)

^f SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN 125; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; RECOMBINANT GLYCOPROTEIN GP 105; RECOMBINANT GLYCOPROTEIN GP 36; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

AFRICA; ANTIGEN ANTIBODY REACTION; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFECTION RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PURIFICATION; VIRUS NEUTRALIZATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE PRODUCTS, ENV; HIV ANTIGENS; HIV INFECTIONS; HIV-2; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFANT; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PROTEIN PRECURSORS; RECOMBINANT PROTEINS;

EID: 2942676472     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.13.7016-7022.2004     Document Type: Article

References (49)

1. Albert, J., U. Bredberg, F. Chiodi, B. Böttiger, E-M. Fenyö, E. Norrby, and G. Biberfeld. 1987. A new human retrovirus isolate of West African origin and its relationship to HTLV-IV, LAV-II and HTLV-IIIB. AIDS Res. Hum. Retrovir. 3:3-10.
2. Andersson, S. 2001. HIV-2 and the immune response. AIDS Rev. 3:11-23.
3. Andersson, S., Z. da Silva, H. Norrgren, F. Dias, and G. Biberfeld. 1997. Field evaluation of alternative testing strategies for diagnosis and differentiation of HIV-1 and HIV-2 infections in an HIV-1 and HIV-2 prevalent area. AIDS 11:1815-1822.
4. Belec, L., P. D. Ghys, H. Hocini, J. N. Nkengasong, J. Tranchot-Diallo, M. O. Diallo, V. Ettiegne-Traore, C. Maurice, P. Becquart, M. Matta, A. Si-Mohamed, N. Chomont, I. M. Coulibaly, S. Z. Wiktor, and M. D. Kazatchkine. 2001. Cervicovaginal secretory antibodies to human immunodeficiency virus type 1 (HIV-1) that block viral transcytosis through tight epithelial barriers in highly exposed HIV-1-seronegative African women. J. Infect. Dis. 184: 1412-1422.
5. Bernard, N. F., C. M. Yannakis, J. S. Lee, and C. M. Tsoukas. 1999. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV exposed seronegative persons. J. Infect. Dis. 179:538-547.
6. Beyrer, C., A. W. Artenstein, S. Rugpao, H. Stephens, T. C. VanCott, M. L. Robb, M. Rinkaew, D. L. Birx, C. Khamboonruang, P. A. Zimmerman, K. E. Nelson, and C. Natpratan. 1999. Epidemiologic and biologic characterization of a cohort of HIV-1 highly exposed, persistently seronegative commercial sex workers in Northern Thailand. J. Infect. Dis. 179:59-67.
7. Biasin, M., S. L. Caputo, L. Speciale, F. Colombo, L. Racioppi, A. Zagliani, C. Ble, F. Vichi, L. Cianferoni, A. M. Masci, M. L. Villa, P. Ferrante, F. Mazzotta, and M. Clerici. 2000. Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J Infect. Dis. 182:1365-1374.
8. Biberfeld, G., R. Thorstensson, M. Bergström, A. Naucler, and C. Mendes Costa. 1988. Enzyme immunoassay for demonstration of the antibodies to HIV-2 SBL6669 and HTLV-IV (SIVmac). AIDS 2:195-199.
9. Björling, E., F. Chiodi, G. Utter, and E. Norrby. 1994. Two V3 associated important neutralizing domains in the envelope glycoprotein gp125 of human immunodeficiency virus type 2. J. Immunol. 152:1952-1959.
10. Björling, E., G. Scarlatti, A. von Gegerfelt, J. Albert, G. Biberfeld, F. Chiodi, E. Norrby, and E.-M. Fenyö. 1993. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 193:528-530.
11. Bock, P. J., and D. M. Markowitz. 2001. Infection with HIV-2. AIDS 15(Suppl. 3):S35-S45.
12. Buseyne, F., S. Le Gall, C. Boccaccio, J. P. Abastado, J. D. Lifson, L. O. Arthur, Y. Riviere, J. M. Heard, and O. Schwartz. 2001. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat. Med. 7:344-349.
13. Cavacini, L. A., M. Duval, J. Robinson, and M. R. Posner. 2002. Interactions of human antibodies, epitope exposure, antibody binding and neutralization of primary isolate HIV-1 virions. AIDS 16:2409-2417.
14. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.
15. Chefalo, P. J., and C. V. Harding. 2001. Processing of exogenous antigens for presentation by class I MHC molecules involves post-Golgi peptide exchange influenced by peptide-MHC complex stability and acidic pH. J. Immunol. 167:1274-1282.
16. Clavel, F., D. Guetard, F. Brun-Vezinet, S. Chamaret, M. A. Rey, M. O. Santos-Ferreria, A. G. Laurent, C. Dauguet, C. Katlama, and C. Rouzioux. 1986. Isolation of a new human retrovirus from West African patients with AIDS. Science 233:343-346.
17. Clerici, M., C. Barassi, C. Devito, C. Pastori, S. Piconi, D. Trabattoni, R. Longhi, J. Hinkula, K. Broliden, and L. Lopalco. 2002. Serum IgA of HIV-exposed uninfected individuals inhibits HIV through recognition of a region within the α-helix of gp41. AIDS 16:1731-1741.
18. Clerici, M., J. M. Levin, H. A. Kessler, A. Harris, J. A. Berzofsky, A. L. Landay, and G. M. Shearer. 1994. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 271:42-46.
19. Clerici, M., J. V. Giorgi, C. C. Chou, V. K. Gudeman, J. A. Zack, P. Gupta, H. N. Ho, P. G. Nishanian, J. A. Berzofsky, and G. M. Shearer. 1992. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J. Infect. Dis. 165:1012-1019.
20. De Kock, K. M., A. Porter, J. Kouadio, M. Maran, M.-F. Lafontaine, G.-M. Gershy-Damet, W. Heyward, and R. George. 1991. Cross-reactivity on Western blots in HIV-1 and HIV-2 infections. AIDS 5:859-863.
21. Devito, C., J. Hinkula, R. Kaul, J. Kimani, P. Kiama, L. Lopalco, C. Barass, S. Piconi, D. Trabattoni, J. J. Bwayo, F. Plummer, M. Clerici, and K. Broliden. 2002. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J. Acquir. Immune Defic. Syndr. 30:413-420.
22. Devito, C., J. Hinkula, R. Kaul, L. Lopalco, J. J. Bwayo, F. Plummer, M. Clerici, and K. Broliden. 2000. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralizes a primary HIV-1 isolate. AIDS 14:1917-1920.
23. Dimmock, N. 1993. Neutralization of animal viruses. Curr. Top. Microbiol. Immunol. 183:32-34.
24. Ferrantelli, F., and R. M. Ruprecht. 2002. Neutralizing antibodies against HIV-back in the major leagues? Curr. Opin. Immunol. 14:495-502.
25. Fowke, K. R., R. Kaul, K. L. Rosenthal, J. Oyugi, J. Kimani, W. J. Rutherford, N. J. Nagelkerke, T. B. Ball, J. J. Bwayo, J. N. Simonsen, G. M. Shearer, and F. A. Plummer. 2000. HIV-1-specific cellular immune responses among HIV-1-resistant sex workers. Immunol. Cell Biol. 78:586-595.
26. Ghys, P. D., L. Belec, M. O. Diallo, V. Ettiegne-Traore, P. Becquart, C. Maurice, J. N. Nkengasong, I. M. Coulibaly, A. E. Greenberg, M. Laga, and S. Z. Wiktor. 2000. Cervicovaginal anti-HIV antibodies in HIV-seronegative female sex workers in Abidjan, Cote d'Ivoire. AIDS 14:2603-2608.
27. Gilljam, G. 1993. Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses. AIDS Res. Hum. Retrovir. 9:431-438.
28. Goh, W. C., J. Markee, R. E. Akridge, M. Meldorf, L. Musey, T. Karchmer, M. Krone, A. Collier, L. Corey, M. Emerman, and M. J. McElrath. 1999. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. J. Infect. Dis. 179:548-557.
29. Herrera, C., C. Spenlehauer, M. S. Fung, D. R. Burton, S. Beddows, and J. P. Moore. 2003. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site. J. Virol. 77:1084-1091.
30. Just, J. J. 1995. Genetic predisposition to HIV-1 infection and acquired immunodeficiency virus syndrome: a review of the literature examining associations with HLA. Hum. Immunol. 44:156-169.
31. Kanki, P. J., S. M'Boup, D. Ricard, F. Barin, F. Denis, C. Boye, L. Sangare, K. Travers, M. Albaum, and R. Marlink. 1987. Human T-lymphotropic virus type 4 and the human immunodeficiency virus in West Africa. Science 236:827-831.
32. Kaul, R., D. Trabattoni, J. J. Bwayo, D. Arienti, A. Zagliani, F. M. Mwangi, C. Kariuki, E. N. Ngugi, K. S. MacDonald, T. B. Ball, M. Clerici, and F. A. Plummer. 1999. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 13:23-29.
33. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 164:1602-1611.
34. Larsen, O., Z. Silva, A. Sandström, P. K. Andersen, S. Andersson, A. G. Poulsen, M. Melbye, F. Dias, A. Nauclér, and P. Aaby. 1998. Declining HIV-2 prevalence and incidence among men in a community study from Guinea-Bissau. AIDS 12:1707-1714.
35. Lizeng, Q., P. Skott, S. Sourial, C. Nilsson, S. Andersson, M. Ehnlund, N. Taveira, and E. Björling. 2003. Serum immunoglobulin A (IgA) mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection. Virology 308:225-232.
36. Lo Caputo, S., D. Trabattoni, F. Vichi, S. Piconi, L. Lopalco, M. L. Villa, F. Mazzotta, and M. Clerici. 2003. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS 17:531-539.
37. MacDonald, K. S., K. R. Fowke, J. Kimani, V. A. Dunand, N. J. Nagelkerke, T. B. Ball, J. Oyugi, E. Njagi, L. K. Gaur, R. C. Brunham, J. Wade, M. A. Luscher, P. Krausa, S. Rowland-Jones, E. Ngugi, J. J. Bwayo, and F. A. Plummer. 2000. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J. Infect. Dis. 181:1581-1589.
38. Marlink, R. 1996. Lessons from the second AIDS virus, HIV-2. AIDS 10: 689-699.
39. Mazzoli, S., D. Trabattoni, S. Lo Caputo, S. Piconi, C. Ble, F. Meacci, S. Ruzzante, A. Salvi, F. Semplici, R. Longhi, M. L. Fusi, N. Tofani, M. Biasin, M. L. Villa, F. Mazzotta, and M. Clerici. 1997. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat. Med. 3:1250-1257.
40. Mazzoli, S., L. Lopalco, A. Salvi, D. Trabattoni, S. Lo Caputo, F. Semplici, M. Biasin, C. Bl, A. Cosma, C. Pastori, F. Meacci, F. Mazzotta, M. L. Villa, A. G. Siccardi, and M. Clerici. 1999. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J. Infect. Dis. 180:871-875.
41. Mörner, A., A. Achour, M. Norin, R. Thorstensson, and E. Björling. 1999. Fine characterization of a neutralizing epitope in the third variable region (V3) of the surface glycoprotein (gp125) of human immunodeficiency virus type 2. Virus Res. 59:49-60.
42. Pastori, C., C. Barassi, S. Piconi, R. Longhi, M. L. Villa, A. G. Siccardi, M. Clerici, and L. Lopalco. 2000. HIV neutralizing IgA in exposed seronegative subjects recognizes an epitope within the gp41 coiled-coil pocket. J. Biol. Regul. Homeost. Agents 14:15-21.
43. Reimann, J., and R. Schirmbeck. 1999. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunol. Rev. 172:131-152.
44. Rowland-Jones, S., J. Sutton, K. Ariyoshi, K. Ariyoshi, T. Dong, F. Gotch, S. Mcadam, D. Whitby, S. Sabally, and A. Gallimore. 1995. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat. Med. 1:59-64.
45. Rowland-Jones, S., T. Dong, K. R. Fowke, J. Kimani, P. Krausa, H. Newell, T. Blanchard, K. Ariyoshi, J. Oyugi, E. Ngugi Bwayo, K. S. MacDonald, A. J. McMichael, and F. A. Plummer. 1998. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Investig. 102:1758-1765.
46. Schim van der Loeff, M. F., and P. Aaby. 1999. Towards a better understanding of the epidemiology of HIV-2. AIDS 13:S69-S84.
47. Skurnick, J. H., P. Palumbo, A. DeVico, B. L. Shacklett, F. T. Valentine, M. Merges, R. Kamin-Lewis, J. Mestecky, T. Denny, G. K. Lewis, J. Lloyd, R. Praschunus, A. Baker, D. F. Nixon, S. Stranford, R. Gallo, S. H. Vermund, and D. B. Louria. 2002. Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. J. Infect. Dis. 185:428-438.
48. Thorstensson, R., L. Walther, P. Putkonen, J. Albert, and G. Biberfeld. 1991. A capture enzyme immunoassay for detection of HIV-2/SIV antigen. J. Acquir. Immune Defic. Syndr. 4:374-379.
49. Wick, M. J., and H. G. Ljunggren. 1999. Processing of bacterial antigens for peptide presentation on MHC class I molecules. Immunol. Rev. 172:153-162.